Johnson Pharma (532154)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Book value per share of ₹1.06 is close to market price of ₹1.14, providing a potential asset floor.
• P/B of 1.08 means the stock trades at only an 8% premium to stated book value.
• Latest quarter's net loss is negligible at ₹-0 Cr, so the loss-making trend is not currently severe in absolute terms.
• Market cap of ₹63 Cr creates room for a small, focused business revival to have an outsized impact.

Concerns

• Sales are ₹0 Cr and sales growth is 0%, so there is no proven revenue engine.
• Profit growth is -100%, ROE is -1.12%, and ROCE is -0.43%; the company is earning below any reasonable cost of capital.
• Piotroski F-Score of 2/9 signals poor financial health and weak overall fundamentals.
• Promoter holding is not disclosed and dividend yield is 0%, offering no visible insider alignment or shareholder return.

AI Analysis

Let me look at Johnson Pharma the way I would any business. First, what does it earn? Nothing. Latest quarter sales are ₹0 Cr, net profit is ₹-0 Cr, and profit growth is -100%. The P/E of 0.00 is not a bargain signal; it is an accounting artifact when earnings are absent. Return on equity is -1.12% and ROCE is -0.43%, so this enterprise is destroying value, not compounding it. The Piotroski F-Score of 2/9 reinforces that: the financial health is poor. So why am I still looking? Because the balance sheet may offer a floor. Book value is ₹1.06 and the stock trades at ₹1.14, a P/B of 1.08. Market cap is ₹63 Cr, so the market is paying only a small premium over stated net worth. That is interesting only if those assets are real, liquid, and honestly valued. I have no evidence of that. With zero revenue, there is no operating engine, no moat, no pricing power. A business that cannot generate sales has no competitive advantage; it is a collection of assets, not a living company. The 52-week range is ₹0.47 to ₹1.14, and the stock sits at its high. That is dangerous: hope has already entered the price. I cannot rely on growth because sales growth is 0%. I cannot rely on dividends because yield is 0%. Promoter holding is not disclosed, so I cannot judge alignment. In Graham's words, price is what you pay, value is what you get. Here I see no earnings, no growth, and a poor Piotroski score. At best this is an asset play, but only if book value holds up under scrutiny. I would demand a margin of safety, not pay book value for a non-earning shell.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer